JP2021523096A5 - - Google Patents
Info
- Publication number
- JP2021523096A5 JP2021523096A5 JP2020556807A JP2020556807A JP2021523096A5 JP 2021523096 A5 JP2021523096 A5 JP 2021523096A5 JP 2020556807 A JP2020556807 A JP 2020556807A JP 2020556807 A JP2020556807 A JP 2020556807A JP 2021523096 A5 JP2021523096 A5 JP 2021523096A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- composition according
- protein
- binds
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671963P | 2018-05-15 | 2018-05-15 | |
| US62/671,963 | 2018-05-15 | ||
| US201962804931P | 2019-02-13 | 2019-02-13 | |
| US62/804,931 | 2019-02-13 | ||
| PCT/US2019/032271 WO2019222252A1 (en) | 2018-05-15 | 2019-05-14 | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523096A JP2021523096A (ja) | 2021-09-02 |
| JP2021523096A5 true JP2021523096A5 (https=) | 2022-05-18 |
| JPWO2019222252A5 JPWO2019222252A5 (https=) | 2022-05-18 |
Family
ID=68540945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556807A Pending JP2021523096A (ja) | 2018-05-15 | 2019-05-14 | 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210061899A1 (https=) |
| EP (1) | EP3813868A4 (https=) |
| JP (1) | JP2021523096A (https=) |
| KR (1) | KR20210009339A (https=) |
| CN (1) | CN112118858A (https=) |
| AU (1) | AU2019271065A1 (https=) |
| BR (1) | BR112020021082A2 (https=) |
| CA (1) | CA3096844A1 (https=) |
| MX (1) | MX2020011638A (https=) |
| SG (1) | SG11202011148VA (https=) |
| TW (1) | TW202003577A (https=) |
| WO (1) | WO2019222252A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020402496A1 (en) * | 2019-12-11 | 2022-06-16 | WuXi Biologics Ireland Limited | Bi-functional antibody against PD-L1 and TGFβ |
| PH12022552826A1 (en) * | 2020-04-28 | 2024-03-11 | Sinocelltech Ltd | Tgfãr2 extracellular domain truncated molecule, fusion protein of tgfãr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein |
| US20230365653A1 (en) * | 2020-07-24 | 2023-11-16 | Mabwell (shanghai) Bioscience Co., Ltd. | Tgf-beta rii mutant and fusion protein thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| CA3081073C (en) * | 2013-03-12 | 2023-09-12 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| EP3497130B1 (en) * | 2016-08-12 | 2021-10-27 | Merck Patent GmbH | Combination therapy for cancer |
-
2019
- 2019-05-14 EP EP19804320.0A patent/EP3813868A4/en not_active Withdrawn
- 2019-05-14 BR BR112020021082-0A patent/BR112020021082A2/pt not_active Application Discontinuation
- 2019-05-14 MX MX2020011638A patent/MX2020011638A/es unknown
- 2019-05-14 KR KR1020207035552A patent/KR20210009339A/ko not_active Withdrawn
- 2019-05-14 AU AU2019271065A patent/AU2019271065A1/en not_active Abandoned
- 2019-05-14 WO PCT/US2019/032271 patent/WO2019222252A1/en not_active Ceased
- 2019-05-14 SG SG11202011148VA patent/SG11202011148VA/en unknown
- 2019-05-14 JP JP2020556807A patent/JP2021523096A/ja active Pending
- 2019-05-14 CN CN201980032533.9A patent/CN112118858A/zh active Pending
- 2019-05-14 CA CA3096844A patent/CA3096844A1/en active Pending
- 2019-05-15 TW TW108116801A patent/TW202003577A/zh unknown
-
2020
- 2020-11-11 US US17/095,377 patent/US20210061899A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2019517549A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| RU2679119C2 (ru) | Лечение неопластических заболеваний | |
| JP2021534094A5 (https=) | ||
| JP2021527083A5 (https=) | ||
| JP2020510039A5 (https=) | ||
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2021523096A5 (https=) | ||
| CN114423453A (zh) | 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2021529777A5 (https=) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| JPWO2019222252A5 (https=) | ||
| JPWO2019241353A5 (https=) | ||
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| CN110996991A (zh) | haNK西妥昔单抗组合和方法 | |
| TW202322855A (zh) | 人類表皮生長因子第二型受體疫苗組成物以及套組 | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| JPWO2019246595A5 (https=) | ||
| CN110494137A (zh) | 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途 |